Literature DB >> 145840

Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor.

G U Corsini, P Onali, C Masala, C Cianchetti, A Mangoni, G Gessa.   

Abstract

Four patients affected by Huntington's chorea (HC) with a well defined family history of the disease were injected intramuscularly with apomorphine hydrochloride in nonemetic doses, ranging from 1 to 4 mg. Soon after treatment, all patients showed a marked decrease in abnormal involuntary movements. Pretreatment with haloperidol (2 mg intramuscularly) or sulpiride (100 mg intramuscularly) 30 minutes prior to apomorphine treatment, prevented the therapeutic effect of this compound. It is suggested that apomorphine-induced improvement in Huntington's Chorea is mediated by the stimulation of a special kind of dopamine receptor, leading to inhibition of the activity of dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 145840     DOI: 10.1001/archneur.1978.00500250031006

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

1.  Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.

Authors:  M Merello; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

2.  (+)-PHNO: a new anti-parkinsonian agent which does not induce chorea in MPTP-treated squirrel monkeys.

Authors:  N M Rupniak; S Boyce; M J Steventon; S D Iversen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

3.  EMD 23,448: effects of a putative dopamine autoreceptor agonist in chorea.

Authors:  R P Newman; C A Tamminga; T N Chase; P A LeWitt
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

4.  Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.

Authors:  S Boyce; N M Rupniak; M J Steventon; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 5.  The corticostriatal pathway in Huntington's disease.

Authors:  Carlos Cepeda; Nanping Wu; Véronique M André; Damian M Cummings; Michael S Levine
Journal:  Prog Neurobiol       Date:  2006-12-13       Impact factor: 11.685

Review 6.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 7.  Advances in the pharmacological management of Huntington's disease.

Authors:  Samuel Frank; Joseph Jankovic
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

8.  Increased paroxysmal activity of partial seizures in man by apomorphine.

Authors:  M Del Zompo; F Tocco; F Marrosu; N Passino; G U Corsini
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.

Authors:  Samuel Frank
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

Review 10.  The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Drugs R D       Date:  2018-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.